LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on the sinusitis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat chondrosarcoma.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Sinusitis: Market analysis
The hollow space, a channel containing blood or a cavity within the bone in the human body is known as a sinus. There are different types of sinuses but, the sinus infection that impacts the spaces behind the head connecting to the nasal cavity is termed as sinusitis. Sinusitis occurs when the mucus starts building up in the nose, inflating the sinuses. Various factors can result in sinusitis, but the major factor that leads to sinusitis is the fluid that gets trapped into the sinus.
According to a senior analyst at Technavio for research on infectious and rare diseases, “There are two different types of sinusitis, including acute sinusitis and chronic sinusitis. Acute sinusitis is the most common type of sinusitis, which makes the cavities around the nasal passage inflamed and swollen. Chronic sinusitis is persistent sinusitis that lasts for more than 12 weeks along with the medical care.”
Sinusitis: Segmentation analysis
This market research report segments the sinusitis market based on therapies employed (monotherapy and unknown), RoA (inhalation, intranasal, oral, subcutaneous, and unknown), therapeutic modalities (monoclonal antibody, biological, small molecule, recombinant protein, and unknown), targets (DNA and RNA, glucocorticoid, IgE receptor, IL-5 receptor, protein, and unknown), MoA (bacterial DNA and RNA modulator, glucocorticoid receptor agonist, IgE receptor inhibitor, IL-5 receptor inhibitor, protein synthesis inhibitor, and protein replacement), and recruitment status (recruiting, active not recruiting, completed, and NA).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 5 molecules that are being investigated for the treatment of sinusitis belong to this category.
Inhalation RoA involves the inhaling of medicines or anesthetics in the form of a gas or a vapor. In the current pipeline, one molecule is administered through the inhalation mode.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.